Faculty profile

Robert Olson

ResearcherRadiation OncologyUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Robert Olson

Researcher

Radiation Oncology

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
27 publications in the last five years, latest in 2026.
Senior (last) author on 5 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,963

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Clinical Trials Metastases Oligometastases Radiation Oncology Stereotactic Ablative Radiotherapy Biomarkers Cost-Effectiveness/Cost-Utility

Latest papers

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)
Prostate · 2026
Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.
Journal of telemedicine and telecare · 2026
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · first author

All 67 publications

Latest funding

Does tailored referral support increase the reach of the Breast Cancer Endocrine Fitness (BE-FIT) program
CIHR · 2025 · Co-investigator
$600,525
Future of Stereotactic Ablative Radiotherapy (SABR) Trials in Oligometastatic Cancer: Continuing Canadian-Led International Investigations in Radiation Therapy
CIHR · 2022 · Nominated PI
$9,980
A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
CIHR · 2019 · Nominated PI
$699,380

All 3 grants and awards

67 publications.

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)

Gouveia AG, Tao J, Pond G, Dong K, Ye A, Rosa AA, Palhares DM, Villafuerte CJQ, Anselmo P, Moraes FY

Prostate2026

DOI: 10.1002/pros.70233

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Powis M, Barbera L, Cheung M, Conrod R, DeVera M, Edwards A, Esmail S, McTaggart-Cowan H, Olson R, Peacock S, Sayani A, Singh S, Ali A, Salmini J, Hack S, Krzyzanowska MK

Journal of telemedicine and telecare2026

DOI: 10.1177/1357633x261469083 PMID: 42573135

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Olson R, Liu M, Bergman A, Mou B, Abraham H, Leclerc C, Carolan H, Schellenberg D, Jiang W, Alexander A, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Gautam D, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S, Baker S

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026First author

DOI: 10.1016/j.radonc.2026.111532 PMID: 42140754

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Leclerc C, Baker S, Jiang W, Mou B, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Chng N, Matthews Q, Benny A, Tyldesley S, Olson R

International journal of radiation oncology, biology, physics2026Senior author

DOI: 10.1016/j.ijrobp.2026.01.012 PMID: 41580164

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

Kooyman A, Chang JS, Liu M, Jiang W, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R, Baker S

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.03.079 PMID: 40216089

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Baker S, Leclerc C, Atmanspacher-Wirth H, Zhao Y, Schellenberg D, Clark H, Mou B, Liu M, Hsu F, Berrang T, Atrchian S, Bergman A, Chng N, Matthews Q, Chang JS, Tyldesley S, Olson R

International journal of radiation oncology, biology, physics2026Senior author

DOI: 10.1016/j.ijrobp.2025.01.031 PMID: 39923903

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P

The Lancet. Oncology2026

DOI: 10.1016/s1470-2045(25)00658-8 PMID: 41643695

Nomogram for Risk-Adaptive Estimation of the Locoregional Control Benefit Following Postoperative Radiation Therapy for Pathologic N0 Oral Cavity Cancer: A Retrospective Analysis.

Gau M, Su J, Huang SH, Alfaraj FA, Olson R, Marta GN, Kowalski LP, Kohler HF, de Matos LL, Moraes FY, Xu W, Sanz-Garcia E, Hahn E, Kim JJ, McPartlin A, O'Sullivan B, Tsai CJ, Waldron J, Prisman E, Irish JC, Yao CMKL, de Almeida JR, Goldstein DP, Hope A, Hosni A

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.09.011 PMID: 40972905

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Willmann J, von Wachter C, Zehnder R, Dee EC, Chen H, Hendriks LEL, Remon J, Baker S, Mayinger M, Andratschke N, Shaverdian N, Gomez DR, Ricardi U, Olson R, Sahgal A, De Ruysscher D, Iyengar P, Guckenberger M

JAMA network open2025

DOI: 10.1001/jamanetworkopen.2025.49685 PMID: 41632169

Virtual Care, What Are We Measuring and What Should We Measure? Scoping Review of Reviews.

Powis M, Ali A, Salmini J, Hack S, Fazelzad R, Barbara L, Berlin A, Cheung M, DeVera M, Edwards A, McTaggart-Cowan H, Olson R, Peacock S, Sayani A, Singh S, Krzyzanowska MK

Journal of medical Internet research2025

DOI: 10.2196/65312 PMID: 41328522

Something wrong or missing on this profile? Suggest a correction

Robert Olson

Research

Latest papers

Latest funding

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

Nomogram for Risk-Adaptive Estimation of the Locoregional Control Benefit Following Postoperative Radiation Therapy for Pathologic N0 Oral Cavity Cancer: A Retrospective Analysis.

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Virtual Care, What Are We Measuring and What Should We Measure? Scoping Review of Reviews.

Does tailored referral support increase the reach of the Breast Cancer Endocrine Fitness (BE-FIT) program

Future of Stereotactic Ablative Radiotherapy (SABR) Trials in Oligometastatic Cancer: Continuing Canadian-Led International Investigations in Radiation Therapy

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3

Frequent collaborators

Devin Schellenberg

Scott Tyldesley

Stewart Gaede

Michael Mckenzie

Anand Swaminath

Alan Nichol

Arjun Sahgal

Ambreen Sayani

Simron Singh

Alison Allan

Stuart Peacock

Helen Mctaggart-Cowan

Melanie Powis

Eitan Prisman

Danielle Rodin

Jennifer Croke

Amanda Caissie

Alejandro Berlin

Arminée Kazanjian

Enrique Sanz Garcia

Laura Dawson

Michael Milosevic

Glenn Bauman

Wei Xu

Michael Peacock

Winson Cheung

Doris Howell

Michael Brundage

Gregory Pond

Andrew Hope

Theos Tsakiridis

George Rodrigues

Winkle Kwan